Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer
Suzanne M Garland, Darron R Brown
Expert Opinion on Biological Therapy | TAYLOR & FRANCIS LTD | Published : 2014
I, Professor SM Garland, have received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, I have received funding through my institution to conduct HPV vaccine studies for MSD and GSK. I am a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV.